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HYDROGEN SULFIDE (H 2 S) was first discovered in 1777 as a colorless gas with a strong "rotten egg" odor. It was thought to be a toxic substance found in sewer gas, swamp gas, and volcanic discharge. Since the discovery that H 2 S reacts to oxyhemoglobin similar to nitric oxide (NO) and carbon monoxide (17) , a number of studies have been carried out to understand the biological functions of H 2 S. The obnoxious odor and toxicity discouraged the attention of researchers until it was revealed that H 2 S may have a possible role as an endogenous neuromodulator (1) . Subsequently, a plethora of investigations were performed on potential roles of H 2 S in cardiovascular disease (CVD), which revealed that physiological levels of H 2 S have a pivotal role in maintaining cardiac function, and an exogenous supply of H 2 S has the potential to ameliorate heart failure in rodents. Empirical studies elucidated several potential mechanisms of H 2 S-mediated cardioprotection in different models of heart failure (21, 117, 123, 128, 150) . However, regulation of H 2 S functions during heart failure is not completely understood. Recently, it was demonstrated that miRNA regulates endogenous H 2 S production (129, 148) . MicroRNAs (miRNAs) are noncoding, regulatory RNAs that modulate gene expression mostly by translational repression (10) . Interestingly, H 2 S also regulates miRNA transcription. However, the crosstalk between H 2 S and miRNAs, and its impact on CVD, is poorly understood. Considering differential expression of miRNAs in CVD (27, 133) , H 2 SmiRNAs crosstalk may have a crucial role in pathophysiology of heart failure. Therefore, H 2 S-miRNA crosstalk is important for understanding H 2 S-mediated cardioprotection. The goal of this review is to summarize the advancements made in H 2 Smediated cardioprotection, highlight the inter-regulation of miRNAs and H 2 S, and emphasize potential future avenues of H 2 S-miRNA crosstalk in CVD, which will provide an impetus for developing H 2 S-based therapeutics for heart disease.
Regulation of H 2 S in vivo. H 2 S is toxic at high levels; therefore, the production and degradation of H 2 S must be tightly regulated in our body to maintain its physiological level. Multiple synthesis and degradation pathways provide a complex interdependence, which could be crucial for restoring the physiological H 2 S level ( Figs. 1 and 2 ). Understanding these pathways is indispensable for developing H 2 S-based therapeutics. H 2 S biosynthesis. H 2 S is predominately and primarily produced by three enzymatic pathways, which include cystathionine ␤-synthase (CBS), cystathionine ␥-lyase (CSE), and the coupling of cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfur transferase (3-MST). CBS, CSE, and CAT are pyridoxal 5-phosphate-dependent enzymes. CBS catalyzes the ␤-replacement of thiosulfides such as homocysteine to cysteine, whereas CSE catalyzes the ␣-and ␥-replacement of cysteine to H 2 S. CAT deaminates cysteine to mercaptopyruvate, which is followed by transulfuration catalyzed by the zinc-dependent enzyme 3-MST that results in biosynthesis of H 2 S. These pathways are elaborated in several excellent review articles (4, 8, 12, 20, 69, 75, 111, 113, 150) and summarized in Fig. 1 . Although CBS and CSE are localized in the cytoplasm, 3-MST is localized mainly in mitochondria but has also been reported in the cytoplasm of vascular endothelial cells ( ) using co-enzyme Q (Co-Q) as the electron acceptor. The enzymes SOD, sulfur transferase (ST), and sulfite oxidase (SO) further oxidize GSSH to thiosulfate or sulfate, which is excreted via the kidneys. Expiration of H2S through exhaled air and scavenging by methemoglobin to sulfhemoglobin are alternative methods of H2S catabolism. 131 ). The expression levels of H 2 S generating enzymes are tissue specific (113) . CSE is the most abundant H 2 S-generating enzyme in the cardiovascular system (83) . Secondary sources of H 2 S include the air we breathe and generation of H 2 S in the gastrointestinal tract by bacterial flora (44, 52, 91, 92) . The multiple pathways for H 2 S synthesis ( Fig. 1) suggest an important role of H 2 S in cell signaling (53, 87, 99, 104) .
Catabolism of H 2 S. High levels of H 2 S are toxic. H 2 S levels are decreased in our body by several catabolic pathways. H 2 S is oxidized to thiosulfate and sulfate in the mitochondria of most mammalian tissues; however, the underlying molecular mechanisms and pathways are poorly understood (11, 69) . Sulfide quinone oxidoreductase, which is located on the inner mitochondrial membrane, oxidizes H 2 S to glutathione persulfide using GSH as the sulfide acceptor (55, 90) . Persulfide dioxygenase or rhodanese catalyze the oxidation of glutathione persulfide to thiosulfate and/or sulfide, which is further oxidized to sulfate by sulfite oxidase (90) . Conversely, Jackson et al. (63) have shown sulfide quinone oxidoreductase catalyzes the oxidation of H 2 S directly to thiosulfate using co-enzyme Q as the electron acceptor and sulfite as the acceptor of sulfane sulfur. Although the intermediate pathways involved in the oxidation of H 2 S are not completely understood, sulfate is the primary by-product of sulfide catabolism, which may be excreted in the urine and feces (63, 69, 90 ). An additional pathway for excretion of H 2 S may include expiration by the lungs (61, 142) . H 2 S may be scavenged by disulfide-containing molecules and red blood cells, where H 2 S binds to methemoglobin forming sulfhemoglobin, which is oxidized to thiosulfate (147) . The multiple pathways for reducing H 2 S levels are presented in Fig. 2 .
Physiological level of H 2 S. Physiological levels of H 2 S range between 15 nM to 300 M in vivo (62, 84, 85, 96, 110, 140, 153, 154) . The wide range of H 2 S levels results from variable detection methods and the tissues analyzed [see review by Liu et al. (96) ]. In in vivo conditions (37°C, pH ϳ7.4), H 2 S is predicted to exist as 14% free H 2 S gas, 86% HS Ϫ , and trace levels of S 2Ϫ (96, 153) . Limitations to measuring H 2 S include 1) free H 2 S has a short half-life, ranging from 12 to 300 s in various species, and 2) detection methods may release bound sulfur from proteins, resulting in increased H 2 S concentrations (61, 96, 142, 153) .
Exogenous sulfur donors. Sodium hydrogen sulfide (NaHS) and sodium sulfide (Na 2 S) are the two most commonly used sources of H 2 S. They are water soluble and cost efficient. However, a limitation of NaHS and Na 2 S is that H 2 S is a volatile substance resulting in evaporation from drinking water. Furthermore, they give more of a bolus effect of H 2 S instead of a slow, steady release (19) . Diallyl disulfide and diallyl trisulfide (DATS) are organic sulfur compounds found in members of the Allium species (garlic, onions, chives, etc.) that act as H 2 S donors and have antioxidant, anti-inflammatory, and vasorelaxant properties (14, 94, 116, 132) . Slow release sulfide donors such as GYY4137 (88) , SG1002 (9, 78, 118) , AP39 (138) , and S-propargyl-cysteine (58, 149) (118) . Because of the volatile nature and short half-life of H 2 S, a continuous, low-level H 2 S release may provide an extended therapeutic potential than a single bolus using high levels as used in many NaHS and Na 2 S studies (19) .
CVD and H 2 S. CVD refers to any disease that leads to dysfunction in the heart and vasculature. Although many therapeutic options are available to treat CVD, the World Health Organization reports CVD remains the leading cause of death globally for both men and women, resulting in 17.5 million deaths in 2012 (155) . Further research and better treatment options are necessary to reduce the incidence and burden of CVD. Evidence is mounting that H 2 S is important in reducing the symptoms associated with CVD. H 2 S reduces hypertension (2, 3), improves glucose uptake and metabolism (9, 89), protects against ischemia-reperfusion (I/R) injury (70, 81, 141, 161) , and decreases cardiac hypertrophy (9, 73, 93, 97) . Further evidence shows that free H 2 S levels are reduced in patients with CVD (64, 79, 118) , suggesting H 2 S supplementation may be a potential therapy for mitigating CVD. However, the underlying molecular mechanisms for H 2 S-mediated improvement in cardiac function, or amelioration of cardiac dysfunction in CVD, are not completely understood.
Diabetic cardiomyopathy is mitigated by H 2 S. Diabetes is among the top 10 causes of death in the United States (25a).
One of the many complications of this debilitating disease is myocardial dysfunction (95, 152) . Diabetes increases the risk of heart failure two-to fourfold as compared with age-and sex-matched nondiabetics (25, 100) . Diabetes may effect both the heart and the vasculature or it may lead to left ventricular heart failure independent of coronary artery disease, a condition known as diabetic cardiomyopathy (26, 95) . Diabetic cardiomyopathy is the end result of chronic exposure to a hyperglycemic environment. The pathophysiology includes cardiac dysfunction due to increased fibrosis and left ventricular hypertrophy (48) . High glucose induces cardiovascular dysfunction by activating the PKC/diacylglycerol pathway, calcium dysregulation, inducing endoplasmic reticulum stress, and deregulating autophagy and apoptosis, which have been shown to be mitigated by H 2 S supplementation (9, 80, 89, 156, 164) . Furthermore, plasma H 2 S levels are decreased in type 2 diabetic patients, high-fat diet-treated mice (type 2 diabetic patients), and streptozotocin-treated rats (9, 64, 66) . The decrease in H 2 S levels in diabetics and the ability of exogenous H 2 S treatment to ameliorate pathological conditions induced by type 1 and type 2 diabetes suggest that H 2 S may be a potential novel treatment option for mitigating cardiomyopathy in diabetics.
H 2 S mitigates I/R injury. Ischemia is the restriction of blood to tissues leading to a decrease in oxygen and glucose. Reperfusion injury occurs when blood flow returns to an area following ischemia and can further exacerbate cell damage (23, 146) . I/R injury leads to increased cardiomyocyte apoptosis (81) . H 2 S reduces reactive oxygen species (ROS) associated with I/R injury as well as decreases in cardiomyocyte apoptosis during ischemia (36, 56, 70, 81, 135, 141, 161) (Table 1) . A major complication following I/R injury is the occurrence of cardiac arrhythmias (37) . H 2 S released by ␣-lipoic acid treatment activates the potassium ATP-sensitive channels (K ATP channels) (37, 67) and decreases post I/R arrhythmias (37) . It was further demonstrated that lower plasma H 2 S levels are associated with greater arrhythmia scores following I/R injury in Wistar rats (137) . NaHS treatment inhibited the L-type Ca 2ϩ channels, activated the K ATP channels, and increased the action potential duration in these rats, all of which may result in decreased arrhythmias (137) . During myocardial I/R injury, delivery of H 2 S at the time of reperfusion reduces infarct size and preserves left ventricular function. Moreover, overexpression of cardiac CSE mitigates myocardial I/R injury (39) . H 2 S may protect the heart from I/R injury by increasing NO bioavailability and signaling (76). These findings suggest that H 2 S treatment may provide protective benefits following I/R injury by decreasing ROS and by mitigating cardiac arrhythmia.
H 2 S is hypotensive. Hypertension (high blood pressure) is defined as having a systolic blood pressure Ͼ140 mm mercury (mmHg) or a diastolic pressure Ͼ90 mmHg (107a, 109). Hypertension is a major medical concern affecting ϳ30% of the United States population (109) . Chronic high blood pressure creates excessive stress on the vasculature, leading to cardiac hypertrophy over time. An initial response to elevated blood pressure is activation of the renin angiotensin aldosterone system (RAAS) (124, 167) . However, chronic activation of the RAAS leads to heart failure (98, 167) . H 2 S inhibits activation of the RAAS in Dahl rats fed with a high-salt diet, mitigating hypertension (59) . Furthermore, abrogation of CSE (involved in H 2 S biosynthesis) decreases the level of H 2 S and induces hypertension in mice (158) . H 2 S may decrease hypertension by opening voltage-dependent potassium channels, resulting in vasorelaxation and increasing vascular tone through multiple mechanisms (77, 125) . H 2 S also induces vasorelaxation by opening K ATP channels (136, 162) and increasing NO production (38) . Contrary to vasorelaxation, Na 2 S and NaHS increased intracavernosal pressure by opening potassium channels in penile tissue (68) , suggesting that H 2 S may cause vasoconstriction in other tissues. Therefore, the role of H 2 S for vasorelaxation or vasoconstriction depends on different conditions and tissues. Nevertheless, H 2 S has multiple mechanisms for reducing hypertension, suggesting a possible therapeutic role for H 2 S supplementation in treating hypertension.
Molecular mechanisms of H 2 S-mediated cardioprotection. The cardioprotective effects of H 2 S are related to several important signaling and regulatory pathways including antioxidant, anti-apoptotic, antifibrotic, and anti-inflammatory regulation (Fig. 3) . (29, 51) . ROS are primarily generated as by-products of oxidative phosphorylation within the mitochondrial electron transport chain (29) . Healthy mitochondria are vital for the overall health of the heart, because mitochondrial ATP generation via oxidative phosphorylation is essential for energy supply and for survival of cardiomyocytes. The generation and removal of ROS are tightly controlled during normal homeostasis but ROS generation increases during pathological conditions (18, 46) . Superoxide radicals activate JNK, which is a stress-activated protein kinase. Induction of JNK leads to the activation of NF-B, an important transcription factor of many cytokines, resulting in cardiac cell death (80) . High glucose (33 mM) treatment increases expression of JNK, NF-B, and the pro-apoptotic marker caspase-3, which resulted in increased apoptosis in cardiomyocytes (80) .
In humans, red blood cells convert organic polysulfide (derived from garlic) into H 2 S, and it is facilitated by allyl substituents (14) . DATS inhibits apoptosis by preventing caspase-3 activation, blunting phosphorylation of JNK and c-JUN, and inhibiting nuclear translocation of NF-B (80). H 2 S mitigates upregulation of ROS and prevents cell death associated with several disease states including hyperglycemia, hyper-homocysteinemia, smoke exposure, and I/R injury (49, 54, 144, 145, 156, 165) .
Nuclear factor erythroid 2 related factor (Nrf2) is a primary regulator for the transcription of antioxidant response elements (72) . NaHS (8 Mol·kg Ϫ1 ·day Ϫ1 ) increases Nrf2 levels in cardiomyocytes, resulting in decreased ROS levels in smokeexposed rats (165) . Furthermore, Nrf2 activation by DATS (10 M) reduces ROS in high glucose-treated cardiomyocytes (143) . In both cases, Nrf2 activation is the result of increased PI3K/Akt signaling induced by H 2 S supplementation (143, 165) . H 2 S administration before myocardial ischemia increases GLUT, glucose transporter; H2S, hydrogen sulfide; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species.
the nuclear localization of Nrf2 and protects the ischemic heart from injury (21). These studies suggest that H 2 S regulates several signaling molecules to suppress oxidants in the heart (Fig. 3) . H 2 S promotes cell survival. Apoptosis or "programmed cell death" can be a protective mechanism at physiological levels for removing damaged cells. However, in pathological conditions, apoptosis is deregulated, which causes increased cell death and tissue damage. As previously mentioned, ROS induces apoptosis and ROS can be mitigated by the antioxidant properties of H 2 S (see H 2 S mitigates I/R injury). In addition, H 2 S inhibits apoptosis by suppressing autophagy (65, 163) . Autophagy is lysosome-mediated degradation and recycling of damaged and/or unnecessary cellular components (84) . NaHS treatment suppresses cigarette smoke-induced upregulation of the autophagy inducers: Beclin-1, LC3II, and AMPK (163). H 2 S not only downregulates autophagy but it also induces PI3K and GSK3␤. PI3K and GSK3␤ upregulate Nrf2 for cardioprotection (65, 143, 165) . In an in vivo I/R model, NaHS (100 M) increased phosphorylated mTOR complex 2, resulting in inactivation of cell death initiator Bim (Bcl-2 interacting mediator of cell death) for cell survival (166). Conversely, GYY4137 (100 M) increases phosphorylated AMPK and decreases mTOR, which prevented high glucose-induced cardiac hypertrophy (151) .
Members of the MAPK family, p38-MAPK and ERK1/2, are upregulated in response to cellular stress, leading to cardiomyocyte apoptosis (50, 156) . p38-MAPK is induced in several disease conditions including hyperglycemia, I/R injury, and hypoxia (16, 49, 50, 134, 156) . NaHS (400 M) inhibits the activation of p38-MAPK in response to the antitumor drug doxorubicin, resulting in decreased apoptosis (50) . Furthermore, pretreatment of H9c2 cardiomyocytes with NaHS (400 M) reduces the cytotoxicity associated with hyperglycemia by inhibiting p38-MAPK and ERK1/2 (156).
These findings demonstrate that H 2 S provides cardioprotection by promoting cell survival via suppressing autophagy and inhibiting multiple proteins involved in apoptosis signaling (Fig. 3) .
H 2 S mitigates pathological cardiac remodeling by inhibiting fibrosis and hypertrophy.
Cardiac fibrosis results from the proliferation of myofibroblasts, leading to increased extracellular matrix deposition in the muscle (34, 47) . Excessive fibrosis decreases contractility and cardiac output and is often associated with cardiomyopathy. NaHS (100 M) reduces fibroblast proliferation in human atrial fibroblast cells (130) . Furthermore, it decreases NADPH oxidase 4, a stimulator of cardiac fibrosis (33) , resulting in decreased levels of the profibrotic markers ␣-smooth muscle actin and connective tissue growth factor (114) . Oral supplementation of SG1002 (20 mg·kg Ϫ1 ·day Ϫ1 ) reduces fibrosis in a transverse aortic constriction model as assessed by Masson Trichrome and Picrosirius Red staining (78). These findings suggest that H 2 S inhibits fibrosis (Fig. 3) , and H 2 S supplementation has a therapeutic potential for decreasing cardiac fibrosis.
Cardiomyocyte hypertrophy occurs in response to chronic increases in pressure or stress. NaHS (100 M) prevents phenylephrine-and isoproterenol-induced hypertrophy in cultured cardiomyocytes and in rat hearts. Furthermore, it downregulates mitochondrial ROS production, apoptosis, and improves glucose uptake through upregulation of the glucose transporters Glut-4 and Glut-1 (89, 97) . The H 2 S donor SG1002 prevents cardiac hypertrophy and cardiac dysfunction by reducing endoplasmic reticulum stress in high-fat diet-fed mice (9) . Our laboratory has demonstrated that H 2 S treatment mitigates cardiac hypertrophy by upregulating miR-133a (73) , an antihypertrophy (24, 41) and antifibrosis (28, 101) microRNA. To increase the levels of miR-133a, H 2 S activates myosin enhancer factor-2c (MEF2C), a transcription factor of miR-133a, by releasing MEF2C from MEF2C-HDAC1 complex (inactivated state) (73) . These studies suggest that H 2 S plays a crucial role in inhibiting cardiac hypertrophy (Fig. 3) .
Anti-inflammatory role of H 2 S. H 2 S treatments reduce inflammation by multiple mechanisms. NaHS and Na 2 S (100 M/Kg body wt) suppress leukocyte adhesion by activating K ATP channels in rats injected with aspirin, an inducer of leukocyte adhesion (160) . Furthermore, inhibition of CSE reduces H 2 S biosynthesis and promotes leukocyte adhesion (160) . H 2 S also regulates NF-B, a transcription factor that is induced in stress, apoptosis, and inflammation signaling. NaHS (400 M) suppresses high glucose-induced increases in NF-B and the pro-inflammatory cytokine IL-1␤ in H9c2 cells (156) . These studies along with the previously mentioned decrease in inflammation in response to I/R injury (subheading 4.2), suggest that H 2 S plays a pivotal role in mitigating inflammation (Fig. 3) . H 2 S regulates microRNAs to ameliorate heart failure. MicroRNAs are small (ϳ22 nt), noncoding RNAs that regulate mRNA and protein expression through mRNA degradation or translational inhibition (10) . MiRNAs are rapidly emerging as therapeutic targets for CVD (22, 103, 108, 122, 126) . H 2 S regulates miRNA expression (70, 73, 93) ; however, the interaction between H 2 S and miRNAs in CVD is poorly understood. Only a few publications document that miRNAs may regulate enzymes that control H 2 S biosynthesis and that H 2 S regulates miRNAs. H 2 S and miRNA inter-regulations are summarized in Fig. 4 .
MiRNAs regulate H 2 S biosynthesis. Three miRNAs, miR-21, miR-22, and miR-30, have been shown to control H 2 S biosynthesis by regulating CSE gene expression. MiR-30 family members are upregulated concomitant with downregulation of CSE in the infarct and border zones following myocardial infarction (MI) in rat hearts (129) . Luciferase reporter assay and in vivo silencing of miR-30 have confirmed that miR-30 targets CSE and inhibition of miR-30 can protect the MI heart by upregulating CSE (129) . Estrogen (E 2 ) also induces CSE expression through estrogen receptor ␣, which upregulates transcription of specificity protein-1 (SP1). SP1 directly binds to the promoter region of CSE to upregulate CSE transcription and H 2 S biosynthesis (148) . Ovariectomized rats have increased levels of myocardial miR-22, which are normalized by E 2 therapy. Furthermore, addition of miR-22 mimic inhibits estrogen receptor ␣ and SP1 and downregulated CSE transcription (148) . This suggests that miR-22 modulates H 2 S production in females. Therefore, E 2 status and its regulation by miR-22 could be crucial in females with CVD. However, the role of anti-miR-22 treatment on cardiac function in males is unclear. It would be an interesting avenue to assess impact of anti-miR-22 treatment on cardiac CSE and H 2 S levels in males. These studies demonstrate that miRNAs play a crucial role in regulating H 2 S biosynthesis (Fig. 4) .
H 2 S regulates miRNAs. Not only do miRNAs regulate the biosynthesis of H 2 S, but H 2 S has also been demonstrated to regulate miRNAs. NaHS (100 M) treatment upregulates cardioprotective miR-133a in primary cultures of neonatal rat cardiomyocytes to inhibit phenylepinephrine-induced cardiomyocyte hypertrophy (93) . Furthermore, Na 2 S (30 M) treatment increased miR-133a level to suppress hyperhomocysteinemia-induced cardiomyocyte hypertrophy in HL1 cardiomyocytes (73). These studies suggest that H 2 S may have an important role in miR-133a-mediated alleviation of cardiac dysfunction. Because diabetic human heart failure patients have reduced levels of miR-133a (107), the role of H 2 S in these hearts will be an interesting area for investigation. Measuring the cardiac levels of H 2 S and designing experiments with late-stage heart failure with H 2 S supplementation will provide insight on H 2 S-mediated cardioprotection in the failing heart.
MiR-1 is a bicistronic transcript with miR-133a and is upregulated in response to I/R stress (70) . I/R-induced apoptosis is mediated through upregulation of miR-1 (70) . MiR-1 is pro-apoptotic and directly suppresses anti-apoptotic proteins including Bcl-2 (70, 139), heat shock protein 60 (127) , and heat Interactions between H2S and microRNAs (miRNAs). MiR-21 and miR-22 inhibit specificity protein 1 [SP1, a transcription factor for cystathionine gamma lyase (CSE)], whereas miR-30 directly inhibits CSE, an enzyme responsible for H2S production, resulting in decreased H2S levels. Estrogen (E) activates estrogen receptor ␣ (ER␣), which binds to SP1 increasing CSE production and H2S. ER␣ also inhibits miR-22, which is an inhibitor of SP1. MiR-22 may also inhibit ER␣, providing a secondary pathway for reducing CSE expression. H2S inhibits miRNAs including miR-221 (anti-neovasculogenic miRNA) and induces miR-133a (antihypertrophy and antifibrotic miRNA). H2S may inhibit and/or induce miR-21, which is a prohypertrophic miRNA but protects the heart during ischemia-reperfusion injury. H2S and miR-21 have crosstalk as miR-21 regulates H2S biosynthesis by inhibiting SP1 and CSE. H2S regulates Bcl-2 (anti-apoptosis) and Akt (anti-oxidant) either directly or via regulating miR-1 and miR-21, respectively. H2S may have synergistic effect on these pathways by direct regulation and indirect via miRNA regulation. PTEN, phosphatase and tensin homolog.
shock protein 70 (159) . The preconditioning of myocardial I/R with H 2 S decreases miR-1-mediated apoptosis (70) . Dietary garlic has a cardioprotective effect, which is mediated through generation of H 2 S in cardiomyocytes and endothelial cells (45, 74) . DATS releases H 2 S (120) and downregulates anti-neovasculogenic miR-221 in a dose-dependent manner (31) . Because miR-221 is upregulated in patients with coronary artery disease, garlic or H 2 S supplementation could be a potential therapeutic strategy for reducing the levels of miR-221 to mitigate the effects of coronary artery disease. The above studies show that H 2 S is involved in regulating miRNAs (Fig. 4) . H 2 S-miRNA crosstalk. The interaction of H 2 S with miRNA is recently uncovered and is an emerging area of investigation. An example of H 2 S-miRNA crosstalk is that H 2 S downregulates miR-21 to mitigate phenylephrine-induced cardiomyocyte hypertrophy (93) , and miR-21 targets SP1 to decrease CSE transcription and H 2 S production (157) . Furthermore, increased miR-21 levels and decreased CSE levels are found in placental tissue from high risk pregnancy as compared with normal pregnancy, suggesting that low H 2 S level may induce miR-21 and contribute to increased pregnancy complications (32) . Perfusion of placental extracts with NaHS improves vasodilation; however, it is unclear whether NaHS perfusion alters miR-21 levels. Although these studies demonstrate that miR-21 may have a negative impact as it reduces H 2 S levels, several studies show the beneficial effects of miR-21 in cardiac cells, including inhibiting apoptosis (30, 121) , protecting cardiomyocytes from H 2 O 2 (30) and I/R damage by suppressing phosphatase and tensin homolog (158) . Na 2 S (10 M) induces miR-21 in primary cardiomyocytes and heart tissue. However, it had no effect on miR-21 knockout mice even though it reduces infarct size and attenuates inflammation in response to I/R injury (141). These findings suggest that H 2 S-miRNA crosstalk may vary in a context-dependent manner and may have different roles in different disease conditions (Fig. 4) . Therefore, more research using different models of heart failure is required to elucidate H 2 S-miRNA crosstalk in CVD.
Potential new areas for investigation on H 2 S-miRNA crosstalk. H 2 S and miRNA are relatively new research areas in CVD, and there is a lot of potential inter-regulation between H 2 S and miRNAs. Although miR-21, miR-22, and miR-30 are demonstrated to modulate CSE gene expression (Fig. 4) , no miRNAs are reported that control CBS or 3-MST expression, suggesting a gap in knowledge. There are ample opportunities for investigations on potential miRNAs regulating genes involved in H 2 S biosynthesis. Furthermore, many miRNAs have been shown to regulate CVD, yet the effect of H 2 S on only a few miRNAs is reported. This provides an avenue to explore the effect of H 2 S on crucial miRNAs involved in the regulation of heart failure. For example, miR-24 is upregulated following MI, and it directly inhibits endothelial NO synthase (102) . H 2 S provides cardioprotective effects through upregulating endothelial NO synthase (76, 78 ), yet it is unclear whether H 2 S suppresses miR-24. Interestingly, H 2 S may regulate anti-apoptotic Bcl-2 by either directly upregulating it or by suppressing miR-1, an inhibitor of Bcl-2. Similarly, H 2 S may regulate Akt directly or by regulating miR-21 (Fig. 4) . Future studies in these areas will elucidate the complex regulatory network of H 2 S-miRNA crosstalk in CVD.
H 2 S involved in clinical trials. Clinical trials with SG1002 will be exciting to follow and to see if the increase in H 2 S levels translate into significant benefits in treating or preventing heart failure. Results from the initial clinical trial with SG1002 have recently been reported, demonstrating that SG1002 increases H 2 S and nitrite levels with few, mild adverse events (118) . Furthermore, sulfur donors are being attached to current drug treatments, such as naproxen, improving their anti-inflammatory effectiveness and decreasing gastrointestinal and cardiovascular side effects (13, 19, 35, 42, 105) . H 2 S has beneficial effects in other organs including neurons, kidney, pancreas, and gastrointestinal and in arthritis (15, 43) . This suggests organ-specific delivery systems for H 2 S may need to be developed to localize therapeutic effects. As H 2 S levels are decreased in diabetics and MI patients, H 2 S may be a useful biomarker for CVD. A clinical trial has been recently completed where H 2 S was measured as a biomarker for peripheral artery disease (clinicaltrials.gov; No. NCT01407172). Another clinical trial is recruiting to measure H 2 S levels in women with CVD (clinicaltrials.gov; No. NCT02180074).
Future directions. Many mechanisms of H 2 S signaling have been elucidated; however, there are still a lot of unknowns on how H 2 S levels influence cardiovascular health. As detection methods improve for more accurate measurements of H 2 S and for measuring real-time H 2 S generation, we will get a better understanding of how cells maintain H 2 S balance. H 2 S mitigates many pathologies associated with CVD, and the therapeutic benefits of H 2 S are currently being explored in other organ systems. For example, H 2 S levels are decreased in the neurodegenerative disorders Alzheimer's and Parkinson's diseases (40, 57) , and H 2 S treatments have mitigated renal dysfunction by many of the same pathways as involved in cardiomyopathy (115) .
The inter-regulation of H 2 S and miRNAs suggests H 2 S may have a greater role in maintaining cellular homeostasis than previously thought. For example, H 2 S may directly regulate Bcl-2 and Akt, or it may control these genes by regulating miR-1 and miR-21, respectively. Besides, H 2 S may have a synergistic effect using direct regulation and indirect regulation via miRNAs (Fig.  4) . More mechanistic studies are required to elucidate the growing role of H 2 S on miRNA regulation and its potential to regulate epigenetic modifications. MiRNAs regulate pathological remodeling in the heart and may be important treatment options for mitigating CVD (103) . Two miRNAs or anti-miRNA therapies are undergoing clinical trial for non-CVD including anti-miR-122 (Miravirsen) for treatment of Hepatitis C (clinicaltrials.gov; No. NCT01200420) (112) and a miR-34 mimic for the treatment of primary liver cancer and other solid tumors (clinicaltrials.gov; No. NCT01829971). The role of these miRNAs on H 2 S or role of H 2 S in the regulation of miRNAs is awaiting.
Long noncoding RNAs (lncRNAs), RNAs with Ͼ200 nucleotides, are emerging as regulators of genes, miRNAs, and proteins involved in CVD (5, 60, 71, 119) . Transcriptome analyses show distinct patterns of lncRNA profiles in heart failure conditions (82, 86) , yet lncRNA-mediated regulation of H 2 S or any effect of H 2 S on lncRNAs is an open area for investigation. Future studies exploring the crosstalk among lncRNAs, miRNAs, and H 2 S may elucidate novel regulatory mechanisms for CVD and provide new strategies for treatment of heart failure.
